The effect of serum CEA expression level on the chemotherapy effect of patients with advanced lung adenocarcinoma

Zongren Wan

Department of Respiratory and Critical Care Medicine, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University,Huai'an 223300, Jiangsu Province, China

Objective: To investigate the effect of serum CEA expression on chemotherapy in patients with advanced lung adenocarcinoma. 

Methods: From August 2018 to June 2019, 90 patients with advanced lung adenocarcinoma who were treated in our hospital were selected as the research objects. After chemotherapy, 46 patients in the middle stage and 44 patients in the late stage were compared and analysed the relationship between efficacy, serum carcinoembryonic antigen level, survival time, and CEA level, as well as the relationship between efficacy and CEA level. 

Result: The level of serum CEA in patients with stage Ⅲ adenocarcinoma was significantly lower than that in patients with stage Ⅳ adenocarcinoma (P < 0.05); there was no significant difference in 1-year survival rate between patients with elevated serum CEA and those with normal serum CEA (P > 0.05); within 3-year and 5-year survival rates, the survival rate of patients with elevated serum CEA was significantly lower than that of patients with normal serum CEA (P < 0.05); the level of CEA in patients with significant efficacy was significantly higher than that before chemotherapy. There was no difference in CEA level before and after chemotherapy (P > 0.05). 

Conclusion: CEA detection in patients with advanced lung adenocarcinoma can effectively reflect the serum level of the body, which can be used as an important index to evaluate the quality of prognosis of patients with lung adenocarcinoma and provide reference for follow-up treatment plans, which has the value of promotion.